Medexus Announces US$51.0 million in New Credit Facilities and Intention to Commence Normal Course Issuer Bid, or NCIB, for its Common Shares Pharmaceutical Investing
NRx Pharmaceuticals, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update Life Science Investing
PharmaTher Advances Strategy to Build Next-Generation Ketamine Franchise for Neuropsychiatric Disorders; Secures Exclusive Rights to Evaluate and License Patented Long-Acting Ketamine Program Life Science Investing
Charles River Laboratories to Present at Jefferies Global Healthcare Conference Life Science Investing
Indaptus Therapeutics Chief Scientific Officer Dr. Michael Newman to Present at the Donor Selection & Cell Source Summit Life Science Investing
Biogen and Stoke Therapeutics Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments Life Science Investing
Stoke Therapeutics and Biogen Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments Life Science Investing
LUPRON DEPOT® new strength receives Health Canada Approval for the Treatment of Advanced Prostate Cancer Pharmaceutical Investing
BioRestorative Granted Type B Meeting with FDA to Discuss Accelerated BLA Approval Pathway for BRTX-100 in Chronic Lumbar Disc Disease Life Science Investing
High Dose Regimen of Nusinersen Receives Positive CHMP Opinion for the Treatment of Spinal Muscular Atrophy Life Science Investing
Incyte Announces Positive CHMP Opinion for Minjuvi® for the Treatment of Relapsed or Refractory Follicular Lymphoma Life Science Investing
Repare Therapeutics Enters into Definitive Agreement to be Acquired by XenoTherapeutics, Inc. Life Science Investing
